This year's Groundhog Day could be equally applicable to the biopharmaceutical industry as well as the weather. The furry rodent saw its shadow, indicating an extended period of winter-like conditions. The performance of leading biopharma companies in February has been just as frosty. Read More
SAN DIEGO – The mood at the Biocom Global Life Science Partnering Conference last week was generally upbeat on the long-term future of the sector, but venture capitalists, investment bankers, serial entrepreneurs, and other speakers at the conference warned that 2016 might be rough for raising capital. Read More
The news earlier this month that Wilmington, Del.-based Incyte Corp. was discontinuing a clinical development program investigating its Janus kinase (JAK) 1 inhibitor Jakafi (ruxolitinib) targeting solid tumors sent the company's shares tumbling about 10 percent. It also disappointed patients suffering from pancreatic cancer, who were hoping that a promising new therapy would be available to them. Read More
